Investor Relations

For information regarding Silence's intellectual property portfolio, please visit the Platform Technologies section.

Stay up to date with our development alerts

>

Submit

DownloadSilence's latest presentation

pdf Silence's Factsheet



Silence Therapeutics plc (LSE: SLN) is a global leader in the discovery, development and delivery of novel RNA interference (RNAi) therapeutics for the treatment of serious diseases. The company possesses one of the world’s most comprehensive RNAi therapeutic platforms comprised of proprietary delivery technologies, potent siRNA sequences and innovative siRNA structural features – the three areas the company believes to be critical to building, protecting and commercialising RNAi therapeutics. The Company’s lead internal drug candidate is Atu027, a liposomal formulation in clinical development for systemic cancer indications and one of the most clinically advanced RNAi therapeutic candidates in the area of oncology. Silence’s product portfolio and technology platforms are protected by a strong intellectual property portfolio.


View Dr. Klaus Giese's presentation slides here

Share Price

▲

1.77p

(+0.155p)

Vol:991131

15-minute delayed


For an updated stock quote, please access the link above to the London Stock Exchange

Registrars

Capita IRG plc
The Registry
34 Beckenham Road,
Kent,
BR3 4TU

Financial Advisors

Singer Capital Markets
One Hanover Street
London, W1S 1YZ

Financial PR

M: Communications
CityPoint,
1 Ropemaker Street - 11th Floor
London, EC2Y 9AW

silencetherapeutics@mcomgroup.com
+44 (0)207 920 2330


Silence Therapeutics News & Articles on Proactiveinvestors